[
  {
    "ts": null,
    "headline": "Moderna's COVID-19 Vaccine Update Boosts Antibodies 16-Fold, Data Shows",
    "summary": "Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE (COVID-19 Vaccine, mRNA), which targets the LP.8.1 variant of SARS-CoV-2. The data from an ongoing Phase 4 clinical trial evaluating the safety, tolerability, and immunogenicity of the 2025-2026 formula of mNEXSPIKE showed, on average, greater than a 16-fold increase in neutralizing antibodies against the LP.8.1 variant in individuals 12 through 64 years of age with at least one",
    "url": "https://finnhub.io/api/news?id=6a8fa97a81f536d7e5673ee28ab02feaab2615987fc96c6f4732e8e4e3aef14e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758756662,
      "headline": "Moderna's COVID-19 Vaccine Update Boosts Antibodies 16-Fold, Data Shows",
      "id": 136879480,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE (COVID-19 Vaccine, mRNA), which targets the LP.8.1 variant of SARS-CoV-2. The data from an ongoing Phase 4 clinical trial evaluating the safety, tolerability, and immunogenicity of the 2025-2026 formula of mNEXSPIKE showed, on average, greater than a 16-fold increase in neutralizing antibodies against the LP.8.1 variant in individuals 12 through 64 years of age with at least one",
      "url": "https://finnhub.io/api/news?id=6a8fa97a81f536d7e5673ee28ab02feaab2615987fc96c6f4732e8e4e3aef14e"
    }
  },
  {
    "ts": null,
    "headline": "Moderna opens new vaccine facility in boost for UK pharmaceutical industry",
    "summary": "The plant in Oxfordshire can make up to 100 million doses per year.",
    "url": "https://finnhub.io/api/news?id=81df3737207d6fbb42b4c3c7db7336867a9b38177c9f0de0a0e75f7266f61f73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758754860,
      "headline": "Moderna opens new vaccine facility in boost for UK pharmaceutical industry",
      "id": 136866427,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The plant in Oxfordshire can make up to 100 million doses per year.",
      "url": "https://finnhub.io/api/news?id=81df3737207d6fbb42b4c3c7db7336867a9b38177c9f0de0a0e75f7266f61f73"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK",
    "summary": "The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population The facility marks a cornerstone of Moderna's ten-year strategic partnership ...",
    "url": "https://finnhub.io/api/news?id=9df7153f7d75775e5b2b7d750f48496245f596174a160fdd66586c15379e3678",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758754860,
      "headline": "Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK",
      "id": 136866426,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population The facility marks a cornerstone of Moderna's ten-year strategic partnership ...",
      "url": "https://finnhub.io/api/news?id=9df7153f7d75775e5b2b7d750f48496245f596174a160fdd66586c15379e3678"
    }
  },
  {
    "ts": null,
    "headline": "Moderna: Maintaining Sell Despite Consolidation - And Why MRNY Won't Help Either",
    "summary": "Discover why Moderna (MRNA) and MRNY ETF present high risks and limited upside for investors. Learn why avoiding both is the best strategy now.",
    "url": "https://finnhub.io/api/news?id=840545eadbafaf44b49412b10e62f593e1822cf06f897534a259b668f083142e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758733190,
      "headline": "Moderna: Maintaining Sell Despite Consolidation - And Why MRNY Won't Help Either",
      "id": 136865085,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1455725431/image_1455725431.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Discover why Moderna (MRNA) and MRNY ETF present high risks and limited upside for investors. Learn why avoiding both is the best strategy now.",
      "url": "https://finnhub.io/api/news?id=840545eadbafaf44b49412b10e62f593e1822cf06f897534a259b668f083142e"
    }
  },
  {
    "ts": null,
    "headline": "Flagship Pioneering, Creator Of Moderna, Launches Extuitive With $20M To Reinvent Consumer Products Using AI Shoppers",
    "summary": "Flagship Pioneering, the Cambridge venture firm known for creating Moderna (NASDAQ:MRNA), last Thursday unveiled a new startup called Extuitive with $20 million in seed funding. The company said the platform is designed to equip small businesses with artificial intelligence tools that simulate consumer behavior, a capability historically used by large corporations. The startup launch represents a change for the 26-year-old firm that built its reputation by fostering life sciences companies worth",
    "url": "https://finnhub.io/api/news?id=563d5d8183cf7564a2c237dfa1ca6afa126b426cbfae3e3d01f4efad89db41c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758675667,
      "headline": "Flagship Pioneering, Creator Of Moderna, Launches Extuitive With $20M To Reinvent Consumer Products Using AI Shoppers",
      "id": 136858320,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Flagship Pioneering, the Cambridge venture firm known for creating Moderna (NASDAQ:MRNA), last Thursday unveiled a new startup called Extuitive with $20 million in seed funding. The company said the platform is designed to equip small businesses with artificial intelligence tools that simulate consumer behavior, a capability historically used by large corporations. The startup launch represents a change for the 26-year-old firm that built its reputation by fostering life sciences companies worth",
      "url": "https://finnhub.io/api/news?id=563d5d8183cf7564a2c237dfa1ca6afa126b426cbfae3e3d01f4efad89db41c1"
    }
  }
]